BRIEF-Ra Pharmaceuticals Initiates Dosing In Phase 2 Clinical Trial Evaluating RA101495 SC
December 21, 2017 at 16:11 PM EST
* RA PHARMACEUTICALS INITIATES DOSING IN PHASE 2 CLINICAL TRIAL EVALUATING RA101495 SC IN GENERALIZED MYASTHENIA GRAVIS PATIENTS
